SAFETY AND EFFICACY OF INTERLEUKIN-17A INHIBITOR (NETAKIMAB) THERAPY FOR MODERATE TO SEVERE PSORIASIS

Purpose. To gain an understanding of the efficacy and safety of Netakimab (interleukin-17A inhibitor) in the treatment of moderate and severe psoriatic skin lesions based on literature review. Materials and methods. Modern Russian and international literature sources on this topic were collected and analysed. Data searches were performed in specialised resources: mrj.ima-press.net, PubMed, Scopus, CochraneLibrary and others. The review focused on the analysis of randomised controlled trials that investigated the efficacy and safety of Netakimab (interleukin-17A inhibitor). Results and discussion. Netakimab has shown a high therapeutic potential is on par with, and in some cases superior to, the efficacy of other biological drugs. A significant proportion of patients achieved PASI 75 and higher by the 12th week of therapy. I Regarding safety, Netakimab demonstrated a profile similar to other IL-17A inhibitors, with no new significant risks identified. Conclusion. Netakimab is a promising first-line biologic therapy option for patients with moderate to severe psoriatic skin lesions. Long-term studies are needed to assess the long-term efficacy and safety of the drug.